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We have read with great interest the “Bottom line” by
Dr. Andrea Bacigalupo titled “Antithymocyte Globulin in the
Conditioning Regimen: Why Not?” on the advantages of the
use of antithymocyte globulin (ATG) for graft-versus-host
disease (GVHD) prevention in patients undergoing alloge-
neic hematopoietic stem cell transplantation (HSCT). Several
studies have shown that ATG reduces the incidence and
severity of acute and chronic GVHD, improving survival [1],
but other studies have alerted us to an increased risk of in-
fectious complications, especially caused by cytomegalovirus
and Epstein-Barr virus, including post-transplantation lym-
phoproliferative disorders (PTLD) [2]. We agree that ATG
reduces the incidence of GVHD but it often has undesirable
consequences, some of them difﬁcult to explain.
From January 1, 2000 to June 30, 2012, 470 patients un-
derwent an allo-HSCT in our center. Of them, 101 received
ATG as part of GVHD prophylaxis (ATGAM [Pﬁzer, New York,
NY], 21 patients, median total dose 40mg/kg; Thymoglobulin
[Genzyme-Sanoﬁ, Lyon, France] 80 patients, median total
dose, 7.5 mg/kg). All patients received acyclovir prophylaxis,
and Epstein-Barr virus DNAemia was determined by an in-
house assay. According to the World Health Organization
deﬁnition [3], 8 patients developed PTLD (7 proven, 1 prob-
able) at a median of 63 days (interquartile range, 48 to 96)
after transplantation, with a surprising temporal aggrega-
tion: all cases were diagnosed after 2010, with a peak inci-
dence of 71% (5 of 7 patients) between December 2011 and
June 2012. The age at transplantation, diagnosis, stem cell
source, and conditioning regimen were heterogeneous.
Among the 7 patients with proven PTLD, 6 were mono-
morphic and 1 was polymorphic. Two patients suffered an
aggressive course with multiorgan failure. Chimerism ana-
lyses showed that tumor cellswere fromdonor origin in 6 of 7
evaluated cases. Despite early treatment with rituximab and/
or chemotherapy, 50% of patients died because of PTLD. These
facts prompted us to stop using Thymoglobulin and to shift to
ATG Fresenius (Neopharm, Bad Homburg, Germany).DOI of original article: http://dx.doi.org/10.1016/j.bbmt.2014.03.011.
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http://dx.doi.org/10.1016/j.bbmt.2014.06.012Because all cases appeared after 2010 without any change
in the ATG dose and regimen or in the transplantation pro-
cedure, we compared patients who received Thymoglobulin
(Genzyme-Sanoﬁ) before January 2010 with those who
received it from this date to July 2012. Except for the per-
centage of patients who underwent transplantation with a
mismatched donor, there were no other signiﬁcant differ-
ences regarding gender, age at transplantation, diagnosis,
disease status, previous lines of treatment, previous HSCT,
stem cell source, or use of ﬂudarabine as part of the condi-
tioning regimen. It is unlikely that the aforementioned single
factor could explain the PTLD outbreak. We also analyzed a
risk score for PTLD development (1 point for each item: T cell
depletion, cord blood, haploidentical SCT, recipient age 50,
matched unrelated donor, mismatched donor, and second
allogeneic SCT) based on previously published risk factors
[4-6], and no statistically signiﬁcant differences were found
between groups. It could be argued that some previous PTLD
cases could have remained undiagnosed, but this is unlikely
because of the high rate of necropsies carried out in our
group (46% of patients who underwent transplantation).
We then considered the possibility of a variation in Thy-
moglobulin (Genzyme-Sanoﬁ) itself as the cause of the
outbreak. ATG is a biological product, not a drug, and, as such,
is highly dependent on the manufacturing process. The
experience with other biological agents demonstrates that
small changes in the manufacturing process can have un-
expected clinical consequences [7]. Surprisingly, in 2007 a
change in the quantity of the thymic source for rabbit im-
munization for Thymoglobulin production was allowed,
without clinical validation. The in vitro tests used for Thy-
moglobulin potency testing only cover a small part of its
broad biological activities and considerable variation is
permitted. Moreover, on August 2012 and March 2014,
several lots of Thymoglobulin were recalled after marketing
because of an unexpected stability failure before the labeled
expiration date. Interestingly, all of our PTLD patients, except
patient number 4, had received 1 of these recalled lots. It is
also signiﬁcant that the switch from Thymoglobulin to ATG-
Fresenius made after July 2012 was correlated with a decline
of PTLD cases, without any differences in patient character-
istics, transplantation procedure, or in the PTLD risk score.
These events were communicated to Spanish Drug Agency
and the manufacturer.
In conclusion, ATG is an effective in vivo T celledepletion
method for graft rejection and GVHD prevention, but it is a
complex biological agent with broad immune effects and
with potential variability [8]. Apart from unanswered ques-
tions, such as the best regimen and dose [9,10], we add
L. Yáñez et al. / Biol Blood Marrow Transplant 20 (2014) 1455e14581458another question to Bacigalupo’s about ATG: Is the same ATG
(Thymoglobulin) always the same? In our experience, the
answer is “no.” This adds confusion in the ATG landscape and
strengthens the need for caution with its use.
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